CN109890827A - 螺环化合物 - Google Patents

螺环化合物 Download PDF

Info

Publication number
CN109890827A
CN109890827A CN201780067175.6A CN201780067175A CN109890827A CN 109890827 A CN109890827 A CN 109890827A CN 201780067175 A CN201780067175 A CN 201780067175A CN 109890827 A CN109890827 A CN 109890827A
Authority
CN
China
Prior art keywords
cancer
compound
pharmaceutically acceptable
acceptable salt
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780067175.6A
Other languages
English (en)
Chinese (zh)
Inventor
黄琴华
穆罕默德·卡赫拉曼
凯文·杜安·邦克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeno Royalty Milestone Co Ltd
Original Assignee
Zeno Royalty Milestone Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalty Milestone Co Ltd filed Critical Zeno Royalty Milestone Co Ltd
Publication of CN109890827A publication Critical patent/CN109890827A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780067175.6A 2016-10-05 2017-10-03 螺环化合物 Pending CN109890827A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
US62/404,668 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (1)

Publication Number Publication Date
CN109890827A true CN109890827A (zh) 2019-06-14

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780067175.6A Pending CN109890827A (zh) 2016-10-05 2017-10-03 螺环化合物

Country Status (13)

Country Link
US (2) US10934304B2 (https=)
EP (1) EP3523306A4 (https=)
JP (2) JP6949952B2 (https=)
KR (1) KR20190075931A (https=)
CN (1) CN109890827A (https=)
AU (1) AU2017339890A1 (https=)
BR (1) BR112019005305A2 (https=)
CA (1) CA3037064A1 (https=)
IL (1) IL265752A (https=)
MX (1) MX2019003938A (https=)
RU (1) RU2019107667A (https=)
TW (1) TW201817732A (https=)
WO (1) WO2018067512A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX379622B (es) 2015-04-03 2025-03-11 Recurium Ip Holdings Llc Compuestos espirociclicos
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
CN112654396B (zh) * 2018-09-07 2025-07-01 默克专利股份公司 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
AU2024374279A1 (en) * 2023-10-31 2026-03-12 C4 Therapeutics, Inc. Compounds for the degradation of mutant braf

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370784A (zh) * 2005-12-13 2009-02-18 先灵公司 为胞外信号调节激酶抑制剂的新颖化合物
WO2013033059A1 (en) * 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
US20140135335A1 (en) * 2012-11-09 2014-05-15 Bristol-Myers Squibb Company Spiro bicyclic oxalamide compounds for the treatment of hepatitis c
CN105732636A (zh) * 2014-12-30 2016-07-06 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2016161160A1 (en) * 2015-04-03 2016-10-06 Kalyra Pharmaceuticals, Inc. Spirocyclic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84930C2 (ru) 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
CA2691417A1 (en) * 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US9447026B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
US9879029B2 (en) 2014-12-22 2018-01-30 Eli Lilly And Company ERK inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370784A (zh) * 2005-12-13 2009-02-18 先灵公司 为胞外信号调节激酶抑制剂的新颖化合物
WO2013033059A1 (en) * 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
US20140135335A1 (en) * 2012-11-09 2014-05-15 Bristol-Myers Squibb Company Spiro bicyclic oxalamide compounds for the treatment of hepatitis c
CN105732636A (zh) * 2014-12-30 2016-07-06 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2016161160A1 (en) * 2015-04-03 2016-10-06 Kalyra Pharmaceuticals, Inc. Spirocyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES F. BLAKE, ET AL.: "Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
CA3037064A1 (en) 2018-04-12
TW201817732A (zh) 2018-05-16
EP3523306A1 (en) 2019-08-14
JP2021193138A (ja) 2021-12-23
EP3523306A4 (en) 2020-05-06
US20210115058A1 (en) 2021-04-22
WO2018067512A1 (en) 2018-04-12
MX2019003938A (es) 2019-06-10
NZ751398A (en) 2021-03-26
RU2019107667A (ru) 2020-11-06
AU2017339890A1 (en) 2019-04-11
WO2018067512A8 (en) 2018-11-01
US10934304B2 (en) 2021-03-02
IL265752A (en) 2019-06-30
JP2019534261A (ja) 2019-11-28
KR20190075931A (ko) 2019-07-01
RU2019107667A3 (https=) 2021-01-27
JP6949952B2 (ja) 2021-10-13
US20200207776A1 (en) 2020-07-02
BR112019005305A2 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
JP6949952B2 (ja) スピロ環化合物
TWI848954B (zh) 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
TWI794297B (zh) 化合物用於製備與第二抗-呼吸道融合性病毒試劑組合使用以治療呼吸道細胞融合病毒感染的藥物之用途及醫藥組合物
TWI705067B (zh) 螺環化合物
EP3828179A1 (en) Cyanopyrrolidines as dub modulators
JP2018524367A (ja) 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン
JP2026506002A (ja) Ｓｏｓ１阻害剤及び抗がん薬を含む、がんの処置のための医薬組成物
TW202317106A (zh) 作為egfr抑制劑之取代胺基吡啶化合物
CN101663276A (zh) 用作激酶抑制剂的2-氨基吡啶衍生物
NZ751398B2 (en) Spirocyclic compounds
HK1256671B (en) Spirocyclic compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: California, USA

Applicant after: Ricoram IP Holding Co., Ltd

Address before: California, USA

Applicant before: Zeno Royalty Milestone Co., Ltd.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190614

WD01 Invention patent application deemed withdrawn after publication